Alnylam scores big pharma support for angiotensinogen silencer

May 26, 2023

You can also search for this author in PubMed Google Scholar

Roche has paid US$310 million upfront, and committed up to $2.5 billion in milestones, to partner with Alnylam on the development and commercialization of zilebesiran, an angiotensinogen-targeted RNAi drug. Zilebesiran is in two ongoing phase II trials for hypertension that are due to read out in 2023 and 2024.

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41573-023-00131-8

We’re seeking a geophysicist with a strong background in either geodynamics, seismology or structural geology to join our team.

Beijing, Hong Kong, Jersey City, Nanjing, New York, Philadelphia, Shanghai or Washington DC (hybrid)

Springer Nature Ltd

DMPK/PD representative in multi-functional expert teams for the evaluation of new chemical entities

Guangzhou, Guangdong, China

BeiGene Ltd.

The Chan Lab in the Human Oncogenesis & Pathogenesis Program at Memorial Sloan Kettering Cancer Center is seeking a highly motivated and successful...

New York City, New York (US)

Memorial Sloan Kettering Cancer Center

The professorship is associated with the management of a department in the field of vegetative physiology.

Tübingen, Baden-Württemberg (DE)

University of Tübingen – Faculty of Medicine

Founded in 1897, Zhejiang University (ZJU) ranks among the top 3 universities on Chinese mainland and within the top 100 in the Times Higher Educat...

Hangzhou, Zhejiang (CN)

Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine(ZJUSS)